The discussion will be on recent advances in our understanding of human gliomas cellular architecture based on scRNAseq and sc multi-omics approaches, across major glioma subsets.

Subsequently, he will also discuss recent work in characterizing the immune micro-environment of gliomas and aspects of cellular cross-talks that impact cellular states and response to therapies.

Mario Suvà is a physician-scientist in the Department of Pathology at Massachusetts General Hospital (MGH) and at the Broad Institute of MIT and Harvard. Suvà’s expertise is in neuro-oncology, single-cell genomics and chromatin analysis.
Suvà's laboratory focuses on the biology of brain tumors, both in adults and children. A particular effort of the laboratory is on dissecting the heterogeneity of diffuse gliomas and relating transcriptional and genetic programs of individual cancer cells. Suvà directed landmark studies characterizing glioblastoma, oligodendroglioma, astrocytoma, pediatric gliomas and medulloblastoma with single-cell genomic technologies, shedding light on tumor heterogeneity, tumor classification, glioma cell lineages, cancer stem cell programs, tumor evolution and the composition of the tumor microenvironment.
Suvà obtained his Ph.D. in Lausanne, Switzerland, studying cancer stem cells in gliomas and sarcomas. He earned his M.D. from the University of Lausanne and his certification in Neuropathology from the Swiss Medical Association. He did his post-doctoral research at MGH and the Broad Institute, applying chromatin analysis and functional approaches to identify master regulators of glioma stem cell programs.